logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Ajanta Pharma Ltd

Ajanta Pharma

Large Cap•8,073 Employees•IPO 2000
Current Price
₹2974.90
58.6 (2.01%)Updated
NSE :AJANTPHARM
BSE :532331
Sector :Pharmaceuticals
Today's Range
₹2900.10
₹2974.90
union icon
₹2988.90
52 Week Range
52W Low₹2327.30
52W High₹3054.00
₹2974.90
union icon
Downside27.83%
Upside2.66%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹36,884.74 Cr
Market Cap
Total market value of company
P/E Ratio
36.36
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
6.97
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹81.21
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
11.98%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
32.40%
ROCE
Return on Capital Employed. >15% is good
Net Margin
19.50%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
6.46%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
12.43%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
13.80%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
3.89%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.01
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹303.44
Book Value
Net asset value per share
Dividend Yield
0.95%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
66.20%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •High Return on Capital Employed (ROCE 32.40%) indicates efficient capital utilization.
  • •Minimal debt-to-equity ratio (0.01) provides strong financial stability and low risk.

Weaknesses

5 points
  • •Elevated P/E ratio (34.23) suggests potential overvaluation compared to earnings.
  • •P/E ratio (32.90) is higher than key peers, limiting upside potential.

Opportunities

5 points
  • •Growing Pharmaceuticals sector benefits from increasing healthcare expenditure and demand.
  • •Robust quarterly sales growth (13.80%) indicates strong market acceptance and expansion.

Threats

2 points
  • •Intense industry competition from large players may cause pricing pressure.
  • •Significant regulatory risks including stringent approvals and evolving drug pricing policies.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
J K TRIPATHI
30 Dec 202431 Dec 2024600
100
₹2,950SELL
J K TRIPATHI
18 Dec 202431 Dec 2024700
100
₹2,895SELL
J K TRIPATHI
29 Nov 202431 Dec 2024800
100
₹3,000SELL
VANDANA SHAILESH SINGH
27 Feb 202528 Feb 2025-
548
₹2,722.45SELL

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹3186.77+₹211.87+7.12%
R3₹3097.97+₹123.07+4.14%
R2₹3043.43+₹68.53+2.30%
R1₹3009.17+₹34.27+1.15%
PIVOT₹2954.63-20.27-0.68%
CURRENT₹2974.90--
S1₹2742.77-₹232.13-7.80%
S2₹2831.57-₹143.33-4.82%
S3₹2865.83-₹109.07-3.67%
S4₹2920.37-₹54.53-1.83%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.85L
(04 Mar 2026)
-19.2% vs avg
Delivery %
54.2%
(04 Mar 2026)
-9.1% vs avg
Avg Volume (20D)
1.05L
(04 Feb - 04 Mar)
20-day average
Avg Delivery %
63.4%
(04 Feb - 04 Mar)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %

Peer Comparison

Company Name
ABBOTINDIA
Abbott India Ltd
ASTRAZEN
Astrazeneca Pharma India Ltd
COHANCE
Cohance Lifesciences Ltd
EMCURE
Emcure Pharmaceuticals Ltd
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
LAURUSLABS
Laurus Labs Ltd
PFIZER
Pfizer Ltd
PPLPHARMA
Piramal Pharma Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
WOCKPHARMA
Wockhardt Ltd

About

AJANTPHARM

Ajanta Pharma Ltd

Ajanta Pharma Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of finished dosage forms of specialty pharmaceuticals. Their product portfolio encompasses both chronic and acute therapies, primarily focusing on branded generic medications. This means they produce medications similar to brand-name drugs once their patents expire, but under their own branding, allowing them to offer more affordable options to consumers.

The company's manufacturing capabilities are diverse, covering a wide range of dosage forms. These include common formats like tablets and capsules, but also extend to more specialized delivery methods such as injectables, inhalers, and topical applications in the form of ointments, creams, and liquids. This broad range of delivery methods allows Ajanta Pharma to cater to a wide variety of medical needs and patient preferences.

Ajanta Pharma's therapeutic focus spans several key areas of healthcare. Their products address conditions related to cardiology (heart health), dermatology (skin conditions), ophthalmology (eye care), and pain management. This strategic focus on specific therapeutic areas allows them to develop expertise and build a strong reputation within those markets.

The company maintains a significant global presence, operating across multiple continents. Their markets include India, where they are headquartered, as well as extensive operations in Africa and Asia. Furthermore, they have established a presence in the United States, a major pharmaceutical market, demonstrating a commitment to international expansion and a broad reach within the global healthcare landscape.

Founded in 1973 and headquartered in Mumbai, India, Ajanta Pharma has a long history in the pharmaceutical industry. Their continued success is likely driven by their diverse product portfolio, comprehensive manufacturing capabilities, focus on key therapeutic areas, and significant global reach. The company's commitment to producing high-quality, affordable medications suggests a continued focus on providing access to essential healthcare worldwide.

COMPANY FACTS - AJANTPHARM

Registered Address

Ajanta House,, Charkop, Kandivli West,

Mumbai

MAHARASHTRA

IN

Tel: 912266061000

Website:https://www.ajantapharma.com/

Investor Relations:http://www.ajantapharma.com/ajanta/Investors/
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 8,073

IPO Date: 05/06/2000

MANAGEMENT - AJANTPHARM

Mr. Mannalal Agrawal

Non-Executive Chairman of the Board

Mr. Madhusudan Agrawal

Executive Vice Chairman of the Board

Mr. Arvind Agrawal

Chief Financial Officer

Mr. Gaurang Shah

Vice President - Legal, Company Secretary

Mr. Rajesh Agrawal

Joint Managing Director, Executive Director

Mr. Yogesh Agrawal

Managing Director, Executive Director

Mr. Rajesh Dalal

Additional Non-Executive Independent Director

Dr. Anjana Grewal

Non-Executive Independent Director

Mrs. Medha Joshi

Additional Non-Executive Independent Director

Mr. David Rasquinha

Additional Non-Executive Independent Director

Ms. Simi Thapar

Additional Non-Executive Independent Director

Investor Questions Answered

Ajanta Pharma Ltd (AJANTPHARM) Stock FAQs

Get answers to the most common questions about Ajanta Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Ajanta Pharma Ltd (AJANTPHARM) is ₹2,974.9. Today, the stock has gained by ₹58.60 (2.01%), trading in a range of ₹2,900.1 to ₹2,988.9. The stock opened at ₹2,905 with a trading volume of 1,11,452 shares.
Ajanta Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹36,884.74 crores, P/E ratio of 36.36, ROE of 11.98%, and ROCE of 32.40%. The dividend yield stands at 0.95%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Ajanta Pharma Ltd (AJANTPHARM) is ₹3,054, while the 52-week low is ₹2,327.3. Currently trading at ₹2,974.9, the stock is 89.1% away from its 52-week low and 2.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Ajanta Pharma Ltd stock at ₹2,974.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 36.36 and P/B ratio of N/A. Today's performance shows a gain of 2.01%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Ajanta Pharma Ltd offers a dividend yield of 0.95%, which means for every ₹100 invested at the current price of ₹2,974.9, you can expect to receive approximately ₹0.95 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Ajanta Pharma Ltd's key financial metrics include: P/E Ratio: 36.36, P/B Ratio: N/A, ROE: 11.98%, ROCE: 32.40%, Dividend Yield: 0.95%, EPS: ₹81.21, Book Value: ₹303.44, Debt-to-Equity: 0.01, and Current Ratio: N/A. The company's market cap stands at ₹36,884.74 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Ajanta Pharma Ltd stock opened at ₹2,905 and is currently trading at ₹2,974.9, showing a gain of ₹58.60 (2.01%). The intraday high is ₹2,988.9 and low is ₹2,900.1. The trading volume stands at 1,11,452 shares, indicating moderate market participation today.
Ajanta Pharma Ltd has a Price-to-Earnings (P/E) ratio of 36.36, which means investors are willing to pay ₹36.36 for every ₹1 of earnings. With an EPS of ₹81.21, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Ajanta Pharma Ltd has a market capitalization of ₹36,884.74 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹2,974.9) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Ajanta Pharma Ltd has a book value of ₹303.44 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹2,974.9, which is 880.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Ajanta Pharma Ltd has a Return on Equity (ROE) of 11.98% and Return on Capital Employed (ROCE) of 32.40%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Ajanta Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Ajanta Pharma Ltd has a debt-to-equity ratio of 0.01, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Ajanta Pharma Ltd has an Earnings Per Share (EPS) of ₹81.21, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹2,974.9 and P/E ratio of 36.36, investors are paying 36.36 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Ajanta Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Ajanta Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Ajanta Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (36.36), ROE (11.98%), debt-to-equity (0.01), and growth rates. 2) Technical Analysis - Check 52-week range (₹2327.30 - ₹3054.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹2974.90) with book value (₹303.44) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Ajanta Pharma Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹2,974.9 is 148645x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Ajanta Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹2327.30 - ₹3054.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.01 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,11,452 shares. 5) Valuation Risk - P/E of 36.36 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Ajanta Pharma Ltd operates in the industry with key metrics: P/E ratio of 36.36, ROE of 11.98%, market cap of ₹36,884.74 crores, and dividend yield of 0.95%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.01), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Ajanta Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹2,974.9, with a 52-week range of ₹2327.30 to ₹3054.00. Based on fundamentals like P/E (36.36), ROE (11.98%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Ajanta Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹2974.90. 2) Fundamental Deterioration - Declining ROE (currently 11.98%), increasing debt (D/E: 0.01), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Ajanta Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.95%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.